Afinitor everolimus regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Afinitor everolimus from Novartis for second-line treatment of advanced renal cell carcinoma (RCC). The agency concluded Afinitor did not provide enough benefit to patients to justify its cost. The FAD is in line with the agency's February preliminary appraisal (see BioCentury, Feb. 15). The oral mTOR inhibitor is approved in the U.K. to treat advanced RCC in patients whose disease has progressed on or after treatment with VEGF-targeted therapy. ...